Academic Journal
Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL).
| Title: | Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL). |
|---|---|
| Authors: | Yu Ri Kim, Jin Seok Kim, Yoo Hong Min, Dok HyunYoon, Ho-Jin Shin, Yeung-Chul Mun, Yong Park, Young Rok Do, Seong Hyun Jeong, Joon Seong Park, Sung Yong Oh, Suee Lee, Eun Kyung Park, Joung-Soon Jang, Won-Sik Lee, Hwe-Won Lee, HyeonSeok Eom, Jae-sook Ahn, Jae-Heon Jeong, Sun Kyung Baek |
| Source: | Journal of Hematology & Oncology; 2012, Vol. 5 Issue 1, p49-57, 9p, 1 Chart, 4 Graphs |
| Abstract: | Background: The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland. Methods: Thirty one patients diagnosed with primary adrenal DLBCL from 14 Korean institutions and treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) were analyzed. Results: Complete remission (CR) and overall response rate after R-CHOP chemotherapy were 54.8% and 87.0%. The 2-year estimates of overall survival (OS) and progression-free survival (PFS) were 68.3% and 51.1%. In patients achieving CR, significant prolongations of OS (P = 0.029) and PFS (P = 0.005) were observed. Ann Arbor stage had no influence on OS. There was no significant difference in OS between patients with unilateral involvement of adrenal gland and those with bilateral involvement. When staging was modified to include bilateral adrenal involvement as one extranodal site, early stage (I or II) significantly correlated with longer OS (P = 0.021) and PFS (P <0.001). Conclusions: Contrary to prior reports, our data suggests that outcomes of primary adrenal DLBCL are encouraging using a regimen of R-CHOP, and that achieving CR after R-CHOP is predictive of survival. Likewise, our modified staging system may have prognostic value. [ABSTRACT FROM AUTHOR] |
| Subject Terms: | B cells, LYMPHOMAS, ADRENAL glands, DRUG therapy, RITUXIMAB, ANTINEOPLASTIC agents, DOXORUBICIN, CANCER treatment |
| Copyright of Journal of Hematology & Oncology is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| ISSN: | 17568722 |
| DOI: | 10.1186/1756-8722-5-49 |
| Database: | Complementary Index |